Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337937 | 0.85 | TRPA1 (0.40) | TRPA1FFAR2RIPK1NR3C2MAOA | |
| SCHEMBL4337943 | 0.85 | TRPA1 (0.40) | TRPA1FFAR2RIPK1NR3C2MAOA | |
| SCHEMBL4521465 | 0.84 | FFAR2 (0.38) | TRPA1FFAR2RIPK1MAOAMAOB | |
| SCHEMBL4521461 | 0.84 | FFAR2 (0.38) | TRPA1FFAR2RIPK1MAOAMAOB | |
| SCHEMBL8038037 | 0.83 | GSK3B (0.38) | GSK3BKCNH2TRPA1FFAR2ACHE | |
| SCHEMBL4521278 | 0.82 | FFAR2 (0.36) | TRPA1FFAR2MAOAMAOB | |
| SCHEMBL4521277 | 0.82 | FFAR2 (0.36) | TRPA1FFAR2MAOAMAOB | |
| SCHEMBL4097126 | 0.78 | FFAR2 (0.43) | TRPA1FFAR2MAOAMAOB | |
| SCHEMBL4092908 | 0.75 | FFAR2 (0.42) | TRPA1FFAR2MAOAMAOB | |
| SCHEMBL22040883 | 0.74 | FFAR2 (0.43) | FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | GSK3B 684/4885KCNH2 2785/4885TRPA1 1300/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | GSK3B 684/4885KCNH2 2785/4885TRPA1 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.